Mechanisms of action of pramipexole: Putative neuroprotective effects

Reviews in Contemporary Pharmacotherapy

Volumn 12, Issue 1-2, 2001, Pages 33-57

  Bennett J P , Jr ^a   Carvey, P M ^a   Hinds, T R ^a   Johnson, R D ^a   Le, W D ^a   Phillips, W ^a   Sethy, V H ^a   Vincenzi, F F ^a   Youdim, M B H ^a  

^a Box 15 ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ACETYLPYRIDINE; CARBIDOPA; DOPA; DOPAMINE; DOPAMINE 3 RECEPTOR; LEVODOPA; METHAMPHETAMINE; NEUROTOXIN; OXIDOPAMINE; PRAMIPEXOLE;

ANIMAL CELL; BRAIN ISCHEMIA; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ELECTRON TRANSPORT; GLIOMA; GRANULE CELL; HUMAN; HUMAN CELL; NERVE CELL DEGENERATION; NEUROBLASTOMA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; RECEPTOR UPREGULATION; REVIEW;

EID: 0034969570     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (227)

1. Oxygen free radicals and Parkinson's disease
2. MPTP-induced oxidative stress and neurotoxicity are age-dependent: Evidence from measures of reactive oxygen species and striatal dopamine loss
3. Brain peroxidase and catalase in Parkinson's disease
4. Central neurotoxic effects of intraperitoneally administered harmaline and niacinamide in Sprague-Dawley and Long Evans rats: A critical review of central 3-acetylpyridine toxicity
5. Permanent parkinsonism in humans due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases
6. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
7. Intranigral iron injection induces behavioral and biochemical 'Parkinsonism' in rats
8. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
9. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up
10. The permeability transition pore. Control points of a CsA-sensitive mitochondrial channel involved in cell death
11. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter
12. Pharmacologically induced changes in the 3′,5′ cyclic guanosine monophosphate content of rat cerebellum cortex: Difference between apomorphine, haloperidol and harmaline
13. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine
14. Bioenergetic and oxidative stress in neurodegenerative diseases
15. The involvement of iron in lipid peroxidation: Importance of ferric to ferrous ratio in initiation
16. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
17. The free radical hypothesis in idiopathic parkinsonism: Evidence against it
18. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism
19. Oxygen-radical absorbance capacity assay for antioxidants
20. A three and a half year experience with pramipexole (PMPX) monotherapy in patients with early Parkinson's disease
21. The case for neuroprotection with dopamine agonists
22. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures
23. Alterations in striatal neurotrophic activity induced by dopaminergic drugs
24. Loss of striatal DA innervation increases striatal trophic activity directed at DA neurons in culture
25. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
26. D3-mediated alterations in mesencephalic-derived neurotrophic activity
27. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease
28. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
29. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-κB in cellular models of Parkinson's disease
30. Bcl-2 promotes regeneration of severed axons in mammalian CNS
31. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites
32. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
33. On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide
34. Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures. I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF)
35. Parkinsonism secondary to intravenous injection of meperidine analogues
36. Effect of piribedil, a D2 dopaminergic agonist, on dopamine, amino acids, free radicals in gerbil brain after cerebral ischemia
37. Curative effect of piribedil, a D2 dopaminergic agonist, in gerbil cerebral ischemia
38. Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischaemia
39. Effect of 3-acetylpyridine on the central nervous system of the rat as demonstrated by silver methods
40. Basal lipid peroxidation in substantia nigra is increase in Parkinson's disease
41. Increased nigral iron content and alterations in other metals occurring in brain in Parkinson's disease
42. Magnetic resonance imaging of brain iron
43. Mechanisms of action of pramipexole: Effects on receptors
44. Studies in Parkinson's disease including x-ray fluorescent spectroscopy of formalin-fixed brain tissue
45. Controversies in the therapy of Parkinson's disease
46. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
47. Unified Parkinson's Disease Rating Scale
48. +-induced apoptosis in human SH-SY5Y neuroblastoma cells
49. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats
50. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo
51. Malonate-induced generation of reactive oxygen species in rat striatum depends upon dopamine release but not on NMDA-receptor activation
52. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: An in vivo microdialysis study
53. MPTP selectively induces haem oxygenase-1 expression in stiatal astrocytes
54. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra
55. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
56. 3H-spiperone binding in rat brain
57. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders
58. Free radical scavengers: Chemical concepts and clinical relevance
59. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
60. 2 and 6-hydroxydopamine
61. 2 induced cell death
62. Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: A second ring is not necessary
63. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
64. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine
65. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine
66. Role of dopamine in ischemic striatal injury
67. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain
68. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
69. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity
70. Effects of R- and S- apomorphine on MPTP-induced nigrostriatal dopamine neuronal loss
71. Gene expression analysis in MPTP model of Parkinson's disease and neuroprotection by apomorphine using cDNA microarray
72. Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine
73. Post-ischemic degeneration of the nigrostriatal tract in gerbil brain: Relationship to increased dopamine release and oxygen radical generation
74. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils
75. 3 agonist pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons
76. The effect of age on the non-haeme iron in human brain
77. Oxidants and the central nervous system: Some fundamental questions
78. Ascorbic acid, metal ions and the superoxide radical
79. Oxygen toxicity, oxygen radicals, transition metals and disease
80. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: A nuclear microscopy study
81. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse
82. Neurologic effects of bcl-2 gene ablation in mice
83. Bcl-2 fluctuations in antioxidant pathway to prevent apoptosis
84. Biochemical physiology of Parkinson's disease
85. Nuclear translocation of NK-κB is increased in dopaminergic neurons of patients with Parkinson's disease
86. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
87. Dopamine metabolism and free radical related mitochondrial injury during transient brain ischemia in gerbils
88. +) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms
89. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
90. Dopaminergic cell death in Parkinson's disease
91. The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease
92. Brain iron and ferritin in Parkinson's and Alzheimer's diseases
93. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates
94. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine parkinsonism in the common marmoset
95. New insights into the cause of Parkinson's disease
96. The pharmacology of selegiline
97. Bcl-2 inhibition of neuronal death: Decreased generation of reactive oxygen species
98. Alzheimer's disease cybrids replicate β-amyloid abnormalities through cell death pathways
99. Glutathione peroxidase activity in Parkinson's disease
100. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice
101. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice
102. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-S75Y cells
103. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease
104. Parkinson's disease and free radicals. Mechanisms of neurodegeneration and neuroprotection
105. Bromocriptine scavanges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum
106. 2+-induced mitochondrial membrane permeabilization: Role of coenzyme Q redox state
107. 2+ is dependent on mitochondrial-generated reactive oxygen species
108. Striatal dopamine participates in glutamate-induced hydroxyl radical generation
109. Clinical pharmacology of dopamine agonists in Parkinson's disease
110. Neuroprotection by dopamine agoinists
111. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
112. MPTP-induced parkinsonism in human and non-human primates: Clinical and experimental aspects
113. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
114. Dopamine agonists used as monotherapy in de novo PD patients: Comparisons with selegiline
115. Role of iron in NF-κB activation and cytokine gene expression by rat hepatic macrophages
116. Dopamine, 6-hydroxydopamine, iron, and dioxygen - Their mutual interactions and possible implications in the development of Parkinson's disease
117. Comparison of the neurotoxicity of dopa stereoisomers in cultured dopamine neurons
118. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures
119. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
120. Effects of enhanced striatal dopamine turnover on in vivo glutathione oxidation
121. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: Implications for Parkinson's disease
122. Brain, skeletal muscle and platelet mitochondrial function in Parkinson's disease
123. Success and problems of long-term levodopa therapy in Parkinson's disease
124. Disability and progression in parkinsonism
125. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal ganglia
126. Overexpression of Bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischaemia
127. Superoxide dismutase: An enzymic function for erythrocuprein (hemocuprein)
128. In vivo formation of single-strand breaks in DNA by hydrogen peroxide is mediated by Haber-Weiss reaction
129. Neurotoxicity of levodopa on catecholamine-rich neurons
130. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture
131. Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to extent of brain dopamine depletion
132. The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide
133. Deficiencies of the respiratory chain in Parkinson's disease
134. Pergolide in the treatment of Parkinson's disease
135. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys
136. +) in ventral mesencephalic-striatal co-culture in rat
137. Histochemical detection of apoptosis in Parkinson's disease
138. Tumor necrosis factor (TNF-α) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients
139. Interleukin-1-beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
140. Bcl-2 protein is increased in the brain from parkinsonian patients
141. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice
142. An endogenous substance of the brain, tetrahydro-isoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions
143. Apoptosis induced by an exogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons
144. +, a metabolite of the neurotoxin MPTP
145. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
146. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease: Final report of a ten-year follow-up
147. Oxidation reactions in Parkinson's disease
148. Brain iron: MRI studies in Parkinson's syndrome
149. Dopamine agonists and neuroprotection in Parkinson's disease
150. 2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia
151. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum
152. Toxic effects of L-DOPA on mesencephalic cell cultures: Protection with antioxidants
153. Abnormalities of the electron transport chain in iodiopathic Parkinson's disease
154. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study
155. Pramipexole vs levodopa as initial treatment for Parkinson's disease
156. + and beta amyloid peptide
157. Idiopathic Parkinson's disease, progressive supranuclear palsy, and glutathione metabolism in the substantia nigra of patients
158. Parkinson's disease: A disorder due to nigral glutathione deficiency?
159. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically
160. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease
161. The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals
162. Mechanisms of MPTP toxicity
163. Double identity for proteins of the Bcl-2 family
164. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brain
165. Dopamine agonists as primary treatment in Parkinson's disease
166. 2+ pump ATPase of intact red blood cells
167. Presence and regulation of tyrosinase activity in human neuroblastoma cell variants in vitro
168. 1-Methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro
169. Meperidine analog exposure in Californian narcotics abusers: Initial epidemiologic findings
170. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra
171. Functional and structural consequences of long-term dietary L-DOPA treatment in mice
172. Transient forebrain ischemia induces delayed injury in the substantia nigra reticulata: Degeneration of GABA neurons, compensatory expression of GAD mRNA
173. Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implications in their mechanisms of action in parkinsonism
174. + toxicity on striatal dopaminergic terminals
175. 2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress
176. Mitochondrial complex I deficiency in Parkinson's disease
177. Mitochondrial complex I deficiency in Parkinson's disease
178. 1 reductase (complex I) deficiency in Parkinson's disease
179. Involvement of free radicals in excitotoxicity in vivo
180. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs
181. Neuroprotective effects of the pyrrolopyrimidine U-104067F in 3-acetylpyridine treated rats
182. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats
183. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases
184. GABA agonist muscimol is neuroprotective in repetitive transient forebrain ischemia in gerbils
185. Oxidative stress in neurodegenerative diseases
186. Hydrogen peroxide production by monoamine oxidase during ischemiareperfusion in the rat brain
187. Mechanisms of the neurotoxicity of MPTP
188. MPTP: A neurotoxin relevant to the pathophysiology of Parkinson's disease
189. Nigral cell loss after methamphetamine treatment in mice
190. Über des eisennacheios im gehirn besonders in zentren des extrapyramidal motorischen system
191. Superoxide-dependent depletion of reduced glutathione by L-dopa and dopamine. Relevance to Parkinson's disease
192. Dopamine turnover and glutathione oxidation. Implications for Parkinson's disease
193. Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies in mice
194. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons
195. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo
196. Morphogenic potentials of D2, D3 and D4 dopamine receptors revealed in transfected neuronal cell lines
197. Origin and functional consequences of the complex I defect in Parkinson's disease
198. Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by antiparkinsonian drugs, talipexole and pramipexole
199. The salicylate hydroxylation assay to measure hydroxyl free radicals induced by local application of glutamate in vivo or induced by the Fenton reaction in vitro
200. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis
201. Early parkinsonism in humans due to MPTP exposure
202. The effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells
203. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation
204. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
205. Pramipexole has antioxidant properties and inhibits lipid peroxidation
206. Stobadine: Bellwether of a broader view of drug actions
207. Pharmacological approaches to counter the toxicity of dopa
208. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine
209. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease
210. Mechanisms of neurodegenerative disorders. Part 1: Protein aggregates
211. Mechanisms of neurodegenerative disorders. Part 2: Control of cell death
212. Do dopamine agonists provide neuroprotection?
213. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
214. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2
215. The role of iron in Parkinson's disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
216. Antioxidant properties of bromocriptine, a dopamine agonist
217. 14C]-deprenyl
218. Brain iron metabolism. Biochemical and behavioral aspects in relation to dopaminergic neurotransmission
219. Iron in the brain: Implications for Parkinson's and Alzheimer's diseases
220. Biogenic monoamine metabolism and functional activity in iron-deficient rats: Behavioural correlates
221. Putative biological mechanisms of the effect of iron-deficiency on brain biochemistry and behavior
222. The possible role of iron in the etiopathology of Parkinson's disease
223. The pivotal role of iron in NF-κB activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators
224. Bcl-2 regulates neural differentiation
225. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
226. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice